Trial Profile
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Dexamethasone; Dexamethasone; Gemcitabine; Oxaliplatin; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 05 May 2020 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2016 Status changed from not yet recruiting to recruiting.